Web2 days ago · Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in … WebDec 13, 2024 · Calliditas ( NASDAQ: CALT) signed a licensing agreement with Viatris ( NASDAQ: VTRS) to register and commercialize Nefecon in Japan for treating chronic autoimmune kidney disease Immunoglobulin A ...

Calliditas Therapeutics has resolved on a directed share ... - Insider

WebFeb 27, 2024 · Summary. Calliditas Therapeutics is a commercial-stage biopharmaceutical company based in Sweden focused on developing and commercializing novel treatments for rare diseases. WebMar 31, 2024 · Calliditas Fireside Chat. Date: Monday, April 3, 2024. Time: 9:00 am ET / 3:00 pm CET. The company will also hold 1x1 meetings with investors at both conferences. For further information, please ... durbin railroad schedule and prices

Calliditas to participate in upcoming investor conferences - Yahoo …

WebApr 11, 2024 · NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced … Web2 days ago · In Japan, Calliditas partnered with Viatris in December 2024 and received a $20 million upfront payment and it can receive up to $80 million in additional milestone payments and royalties on net ... WebJul 21, 2024 · Calliditas and STADA partner to bring a specialty therapy focused on downregulating IgA1 to European patients. If approved, it would be the first-ever approved treatment in the EU for chronic autoimmune kidney disease IgA Nephropathy (IgAN) Partnership for this oral orphan-drug candidate combines Calliditas’ drug-delivery … cryptocephalus coryli